In a 13G filing on AVANT Immunotherapeutics (Nasdaq: AVAN), TSP Capital Management disclosed a 10.06% stake (7,563,867 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE